OTL nach dem RS 1:20 WKN: A4046T ISIN: US69012T3059 Kürzel: OTLK Forum: Aktien User: Pinoy80

1,47 EUR
-3,61 % -0,06
29. Juni 2026, 23:00 Uhr, Lang & Schwarz
Kommentare 10.465
Böserjunge
Böserjunge, 5. Jun 16:08 Uhr
0

Also wenn ich sofort erneut poste, könnte mich das System gänzlich sperren, Spamverdacht u.s.w. Ist jemand bei Reddit und könnte die neue Version bei Reddit USA posten ? : Financial Analysis on Outlook Therapeutics ($OTLK): Why Dilution Concerns Might Be Overstated : The recent market reaction surrounding Outlook Therapeutics ($OTLK) regarding the potential authorization of 340 million new shares and a Reverse Split (RS) seems exaggerated when looking closely at the actual financials and timeline.Here is a realistic breakdown of the math:The Science is Settled: The OND has granted the appeal, confirming Norse TWO and Norse EIGHT prove efficacy for LYTENAVA. The regulatory risk is drastically reduced as we head into the 60-day Class 1 Resubmission cycle.Existing Shares are Sufficient: People often overlook that management already has 43 million shares available. If the stock reaches a post-approval price between $1.00 and $2.00, utilizing these existing shares alone could generate between $43M and $86M. This is more than enough to completely fund the initial commercial rollout.Controlled Placement & Minor Dips: Instead of a massive crash, a piece-by-piece placement of these 43 million shares into a rising market would only cause a minor, healthy dip in the share price (for example, a temporary drop from $2.00 down to $1.80). This minor fluctuation is a completely normal market reaction, but it fully finances the commercial rollout without destroying shareholder value.No Immediate Need for 340M Shares: With $5M from the recent direct offering and $18.4M in unsecured credit lines, the company has enough runway to reach the finish line. Massive immediate dilution makes zero sense mathematically when the stock is at $0.80. The 340M request serves as a long-term financial safety net, not an immediate threat to shareholders.Conclusion: The current fundamentals remain very strong, and the math indicates that fears of near-term dilution are mathematically illogical.

Sieh was du angerichtet hast: AMIS KÖNNEN NUR BILDER!!!.....🤣🤣🤣
Ido89
Ido89, 5. Jun 16:04 Uhr
0
Wenn ich mir die Watchlist wieder ansehe dominiert gerade ganz klar die Rote Farbe
Ido89
Ido89, 5. Jun 16:03 Uhr
0
OTLK hält sich im Vergleich zu den anderen aber gut
U
Un_bekannt12, 5. Jun 16:02 Uhr
0

Langsam werden Sie wach

Ja und verkaufen erstmal fleißig ihre aktien
Ido89
Ido89, 5. Jun 15:46 Uhr
0
Langsam werden Sie wach
Markus68
Markus68, 5. Jun 15:45 Uhr
1

Also wenn ich sofort erneut poste, könnte mich das System gänzlich sperren, Spamverdacht u.s.w. Ist jemand bei Reddit und könnte die neue Version bei Reddit USA posten ? : Financial Analysis on Outlook Therapeutics ($OTLK): Why Dilution Concerns Might Be Overstated : The recent market reaction surrounding Outlook Therapeutics ($OTLK) regarding the potential authorization of 340 million new shares and a Reverse Split (RS) seems exaggerated when looking closely at the actual financials and timeline.Here is a realistic breakdown of the math:The Science is Settled: The OND has granted the appeal, confirming Norse TWO and Norse EIGHT prove efficacy for LYTENAVA. The regulatory risk is drastically reduced as we head into the 60-day Class 1 Resubmission cycle.Existing Shares are Sufficient: People often overlook that management already has 43 million shares available. If the stock reaches a post-approval price between $1.00 and $2.00, utilizing these existing shares alone could generate between $43M and $86M. This is more than enough to completely fund the initial commercial rollout.Controlled Placement & Minor Dips: Instead of a massive crash, a piece-by-piece placement of these 43 million shares into a rising market would only cause a minor, healthy dip in the share price (for example, a temporary drop from $2.00 down to $1.80). This minor fluctuation is a completely normal market reaction, but it fully finances the commercial rollout without destroying shareholder value.No Immediate Need for 340M Shares: With $5M from the recent direct offering and $18.4M in unsecured credit lines, the company has enough runway to reach the finish line. Massive immediate dilution makes zero sense mathematically when the stock is at $0.80. The 340M request serves as a long-term financial safety net, not an immediate threat to shareholders.Conclusion: The current fundamentals remain very strong, and the math indicates that fears of near-term dilution are mathematically illogical.

Ich könnte es bei Stocktwits posten wenn du magst.
U
Un_bekannt12, 5. Jun 15:42 Uhr
0
Dafür ist bei mir alles außer OTK in einer hübschen roten Farbe angefärbt 🙄😝
U
Un_bekannt12, 5. Jun 15:39 Uhr
0
Da kommen wir nichts mal an die 0,74€ von heute Morgen dran...
Ido89
Ido89, 5. Jun 15:39 Uhr
0
Keine Kohle mehr 🤣
U
Un_bekannt12, 5. Jun 15:39 Uhr
0

Amis haben kein bock heute

So schauts aus, da tut sich heute nicht viel 😴
Ido89
Ido89, 5. Jun 15:37 Uhr
0
Amis haben kein bock heute
M
MacFat, 5. Jun 15:26 Uhr
0
Vamooos ♿♿
M
MacFat, 5. Jun 15:26 Uhr
0
Meine Multitasking Station im Auto hat leider ihre Grenzen
R
Rpunkt, 5. Jun 15:22 Uhr
0

Sorgst du gerade dafür das die Amis schön Kaufen 😉

Also wenn ich sofort erneut poste, könnte mich das System gänzlich sperren, Spamverdacht u.s.w. Ist jemand bei Reddit und könnte die neue Version bei Reddit USA posten ? : Financial Analysis on Outlook Therapeutics ($OTLK): Why Dilution Concerns Might Be Overstated : The recent market reaction surrounding Outlook Therapeutics ($OTLK) regarding the potential authorization of 340 million new shares and a Reverse Split (RS) seems exaggerated when looking closely at the actual financials and timeline.Here is a realistic breakdown of the math:The Science is Settled: The OND has granted the appeal, confirming Norse TWO and Norse EIGHT prove efficacy for LYTENAVA. The regulatory risk is drastically reduced as we head into the 60-day Class 1 Resubmission cycle.Existing Shares are Sufficient: People often overlook that management already has 43 million shares available. If the stock reaches a post-approval price between $1.00 and $2.00, utilizing these existing shares alone could generate between $43M and $86M. This is more than enough to completely fund the initial commercial rollout.Controlled Placement & Minor Dips: Instead of a massive crash, a piece-by-piece placement of these 43 million shares into a rising market would only cause a minor, healthy dip in the share price (for example, a temporary drop from $2.00 down to $1.80). This minor fluctuation is a completely normal market reaction, but it fully finances the commercial rollout without destroying shareholder value.No Immediate Need for 340M Shares: With $5M from the recent direct offering and $18.4M in unsecured credit lines, the company has enough runway to reach the finish line. Massive immediate dilution makes zero sense mathematically when the stock is at $0.80. The 340M request serves as a long-term financial safety net, not an immediate threat to shareholders.Conclusion: The current fundamentals remain very strong, and the math indicates that fears of near-term dilution are mathematically illogical.
M
MamaCoona, 5. Jun 15:16 Uhr
0

Der Titel war wohl zu heftig, die Plattformen haben mich jetzt stummgeschaltet 🫢 Die KI gibt sich bedrõppelt, hat den Text entschärft, eine neue Version entworfen, rät einen Tag zu warten...

🤣🤣🤣
Ido89
Ido89, 5. Jun 15:10 Uhr
0

Der Titel war wohl zu heftig, die Plattformen haben mich jetzt stummgeschaltet 🫢 Die KI gibt sich bedrõppelt, hat den Text entschärft, eine neue Version entworfen, rät einen Tag zu warten...

🤣🤣🤣
Mehr zu diesem Wert
Thema
1 OTL nach dem RS 1:20
2 OTL
Meistdiskutiert
Thema
1 für alle, die es ehrlich meinen beim Traden.
2 Trading- und Aktien-Chat
3 MICRON TECHNOLOGY Hauptdiskussion +0,44 %
4 Das neue Germany 40 Prognose Forum +0,37 %
5 Canopy Hauptforum +5,71 %
6 Germany 40 Hauptdiskussion +0,37 %
7 Volatus Aerospace (Offener Austausch) -0,18 %
8 APOLLO MINERALS Hauptdiskussion +1,56 %
9 Novo Nordisk nach Split +0,85 %
10 Freunde der Tellekom -4,37 %
Alle Diskussionen
Aktien
Thema
1 MICRON TECHNOLOGY Hauptdiskussion +0,48 %
2 Canopy Hauptforum +5,71 %
3 Volatus Aerospace (Offener Austausch) -0,18 %
4 APOLLO MINERALS Hauptdiskussion +1,56 %
5 Critical Infrastructure Technologies Hauptdiskussion -20,46 %
6 Novo Nordisk nach Split +0,85 %
7 Freunde der Tellekom -4,37 %
8 MICROSOFT Hauptdiskussion -0,49 %
9 LanzaTech Global Registered Hauptdiskussion +8,58 %
10 VW Hauptdiskussion -8,86 %
Alle Diskussionen